ITI Value Fund Direct - Growth
ITI Value Fund Direct - Growth: Mutual Fund Overview
ITI Value Fund Direct - Growth is an Value Oriented mutual fund with over 4.74 years of performance history. The scheme manages an AUM of ₹344.58 Cr and has a NAV of ₹17.7311. It is rated '2' stars by analysts. Investors can begin a SIP with as little as ₹500.0, making it accessible for all types of investors. In the last 1 year, the fund has delivered a return of 13.41%.
Equity, Value Oriented, Principal at very high risk
1 Year Return 13.41% at 12 Mar 2026 07:32 PM
Fund Details
NAV 17.7311
Sub-Type Value Oriented
Rating 2
Min. SIP Amount ₹500.0
Fund Age(Year) 4.74
Fund Size(in Crores) 344.58
Fund Performance
1 Month -6.62%
3 Month -3.57%
6 Month -0.75%
1 Year 13.41%
3 Year 18.59%
5 Year 0.0%
Know This Fund
As on 12 Mar 2026
Investment strategy that balances risk & reward by dividing the investment portfolio among different types of asset classes.
Equity (99.68%) Market Cap Mid Cap 27.12 Small Cap 33.23 Large Cap 39.33 Top Sectors Healthcare 99.68 Top Holding Novartis AG 2.28 Torrent Pharmaceuticals 3.46 AbbVie Inc 2.91 Fortis Healthcare 3.12 Vertex Pharmaceuticals Inc. (USA) 0.9 Glenmark Pharmaceuticals 2.24 Medtronic 0.89 Laurus Labs 2.55 Zydus Lifesciences 1.25 Narayana Hrudayalaya 0.88 Johnson & Johnson 4.25 Lupin 3.9 Alkem Laboratories 1.82 Amgen Inc. (USA) 1.48 Biocon 1.41 Ipca Laboratories 1.44 Agilent Technologies Inc 0.24 Syngene International 0.52 Divi's Laboratories 5.17 Global Health 0.62 Stryker Corp 0.94 Dr. Reddy's Laboratories 4.71 Iqvia Holdings 0.21 Intuitive Surgical Inc. (USA) 1.27 Gland Pharma 0.91 Illumina Inc. (USA) 0.14 Mankind Pharma 1.88 Abbott Laboratories 1.42 Aurobindo Pharma 2.15 Aster DM Healthcare 1.03 Apollo Hospitals Enterprise 5.69 Regeneron Pharmaceuticals Inc 0.58 Becton Dickinson And Co 0.36 Ajanta Pharma 0.88 Gilead Sciences Inc. (USA) 1.31 Glaxosmithkline Pharma 0.73 Thermo Fisher Scientific Inc 1.37 Merck & Co Inc (US) 2.2 Eli Lilly 6.01 Sun Pharmaceutical Industries 11.25 Max Healthcare Institute 5.73 Piramal Pharma 0.63 Cipla 5.14 Novo Nordisk A/S - ADR 0.86 Danaher Corporation 0.95
Debt & Others (0.32%) Sector Allocation Net Receivables 0.17 Cash 0 CBLO 0.15 Debt Credit Ratings Debt Category Others 0.32
Comparison with same funds
Equity, Flexi Cap funds Aditya Birla Sun Life Pharma & Healthcare Fund Regular-Growth Ret 1M 1.98% Ret 1Y 11.98% Ret 3Y 24.68% Ret 5Y 14.39%
Equity, Flexi Cap funds Aditya Birla Sun Life Pharma & Healthcare Fund Regular-IDCW Ret 1M 1.98% Ret 1Y 11.98% Ret 3Y 24.68% Ret 5Y 14.39%
Equity, Flexi Cap funds Aditya Birla Sun Life Pharma & Healthcare Fund Regular-IDCW Reinvestment Ret 1M 1.98% Ret 1Y 11.98% Ret 3Y 24.68% Ret 5Y 14.39%
Equity, Flexi Cap funds Bajaj Finserv Healthcare Fund Regular-Growth Ret 1M -0.57% Ret 1Y 8.51% Ret 3Y 0% Ret 5Y 0%
Equity, Flexi Cap funds Bajaj Finserv Healthcare Fund Regular-IDCW Payout Ret 1M -0.57% Ret 1Y 8.51% Ret 3Y 0% Ret 5Y 0%
Equity, Flexi Cap funds Bajaj Finserv Healthcare Fund Regular-IDCW Reinvestment Ret 1M -0.57% Ret 1Y 8.51% Ret 3Y 0% Ret 5Y 0%
Equity, Flexi Cap funds Bandhan BSE Healthcare Index Fund Regular-Growth Ret 1M 1.7% Ret 1Y 11.07% Ret 3Y 0% Ret 5Y 0%
Equity, Flexi Cap funds Bandhan Healthcare Fund Regular - Growth Ret 1M 1.28% Ret 1Y 0% Ret 3Y 0% Ret 5Y 0%
Equity, Flexi Cap funds Bandhan Healthcare Fund Regular - IDCW Ret 1M 1.28% Ret 1Y 0% Ret 3Y 0% Ret 5Y 0%
Equity, Flexi Cap funds Bandhan Healthcare Fund Regular - IDCW Reinvestment Ret 1M 1.28% Ret 1Y 0% Ret 3Y 0% Ret 5Y 0%
Equity, Flexi Cap funds Baroda BNP Paribas Health and Wellness Fund Regular-Growth Ret 1M 1.41% Ret 1Y 0% Ret 3Y 0% Ret 5Y 0%
Charges & Taxes Expense Ratio
Returns are taxed as per your Income Tax Slab.
Expense Ratio (Inclusive of GST): 0.57%
Exit Load 0.5%
Stamp Duty 0.005%
Fund Management
The various expenses, charges and taxes associated with your Mutual Fund
Rohan Korde
Education Mr. Korde is a Masters in Management Studies (Finance), Bachelor of Commerce
Experience Prior to joining ITI Mutual Fund, he has worked with BOB Capital Markets as Vice President
Dhimant Shah
Education Mr. Shah is a B.Com (H) and Chartered Accountant.
Experience Prior to joining ITI Mutual Fund, he has worked with Principal Mutual Fund, HSBC AMC, Reliance Mutual Fund, ASK Raymond James Securities Pvt. Ltd. and IL&FS AMC. Senior Analyst from April 1997 to August 2003.
Rajesh Bhatia
Education Mr. Bhatia has done B.Com, ACMA and CFA
Experience Prior to joining ITI Mutual Fund, he was associated with The Investment Trust Of India Ltd, Simto Investment Company Ltd, ProAlpha Systematic Capital, Heritage India Advisors Ltd and Reliance Capital Asset Management Ltd
Riskometer
Mutual Fund Investments are subject to market risk. Read all scheme related documents carefully.
Principal at very high risk
AMC and Fund details
Rank (total sets) 16
Date of Incorporation 2021-06-14
Total AUM 10936.13
The Scheme Seeks to generate returns from a portfolio of pure debt oriented funds accessed through the diverse investment styles of underlying schemes selected in accordance with the BSLAMC process.
Take Your Next Step
